ACELYRIN (SLRN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.09 (-4.09%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of ACELYRIN (SLRN)
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.

Key Insights

Critical company metrics and information

  • Share Price

    $2.26

  • Market Cap

    $226.74 Million

  • Total Outstanding Shares

    100.33 Million Shares

  • Total Employees

    130

  • Dividend

    No dividend

  • IPO Date

    May 5, 2023

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Phone Number

    805-871-4300

  • Address

    4149 liberty canyon rd., Agoura hills, CA, 91301

  • Homepage

    https://www.acelyrin.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$165.87 Million
Net Cash Flow From Financing Activities, Continuing$1.01 Million
Net Cash Flow, Continuing$88.12 Million
Net Cash Flow From Financing Activities$1.01 Million
Net Cash Flow From Investing Activities, Continuing$165.87 Million
Net Cash Flow From Operating Activities$-78.76 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations After Tax$-48.55 Million
Operating Income/Loss$-54.75 Million
Net Income/Loss$-48.55 Million
Operating Expenses$54.75 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Accounts Payable$17.55 Million
Assets$618.31 Million
Liabilities$90.03 Million
Equity$528.28 Million
Other Non-current Assets$20.02 Million
Liabilities And Equity$618.31 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.